Separately, results from the genetic study suggest prophylactic 5-HT2B inhibition may be sufficient for attenuating CAVD initiation, but therapeutic inhibition is insufficient for slowing the progression of existing disease. The gene discussed is HTR2B; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.